All In Biotech

Drug Trial Radar · NCT06952803

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

A Randomised, Double-blind, Placebo-controlled, Phase III Study of Adjuvant Saruparib (AZD5305) in Patients With BRCAm Localised High-Risk Prostate Cancer Receiving Radiotherapy With Androgen Deprivation Therapy (EvoPAR-Prostate02).

Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 700 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

700

Planned (sponsor's estimate)

Start

Aug 6, 2025

Primary completion

Mar 31, 2033

Study completion Apr 30, 2036

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Parexel
First posted
May 1, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival in participants with high-risk and very high-risk localised/locally advanced prostate cancer with a breast cancer gene mutation (BRCAm).

Conditions

  • Prostate Cancer

Interventions

  • SaruparibDrug

    Saruparib will be administered orally.

  • PlaceboDrug

    Matching placebo to saruparib will be administered orally.

  • Abiraterone + Prednisolone/PrednisoneDrug

    Abiraterone will be administered orally in combination with prednisone/prednisolone.

  • Androgen Deprivation Therapy (ADT)Drug

    Standard of care ADT will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Metastasis-free survival (MFS)Time frame: Up to approximately 93 months

Locations

346 sites in 28 countries. Site status is shown where the registry gives one.

  • Research Site

    Phoenix, Arizona · Recruiting

  • Research Site

    Tucson, Arizona · Withdrawn

  • Research Site

    La Jolla, California · Recruiting

  • Research Site

    La Jolla, California · Recruiting

  • Research Site

    Los Angeles, California · Recruiting

  • Research Site

    San Diego, California · Recruiting

  • Research Site

    San Luis Obispo, California · Recruiting

  • Research Site

    Lakewood, Colorado · Recruiting

  • Research Site

    Hialeah, Florida · Recruiting

  • Research Site

    Jacksonville, Florida · Recruiting

  • Research Site

    Tallahassee, Florida · Withdrawn

  • Research Site

    Tampa, Florida · Recruiting

  • Research Site

    Newnan, Georgia · Recruiting

  • Research Site

    Chicago, Illinois · Recruiting

  • Research Site

    Chicago Ridge, Illinois · Recruiting

  • Research Site

    Lake Barrington, Illinois · Withdrawn

  • Research Site

    Greenwood, Indiana · Recruiting

  • Research Site

    Jeffersonville, Indiana · Withdrawn

  • Research Site

    Bethesda, Maryland · Withdrawn

  • Research Site

    Towson, Maryland · Recruiting

  • Research Site

    Plymouth, Massachusetts · Recruiting

  • Research Site

    Rochester, Minnesota · Recruiting

  • Research Site

    Hackensack, New Jersey · Recruiting

  • Research Site

    Voorhees Township, New Jersey · Recruiting

  • Research Site

    Albany, New York · Withdrawn

  • Research Site

    New York, New York · Recruiting

  • Research Site

    Syracuse, New York · Recruiting

  • Research Site

    Columbus, Ohio · Recruiting

  • Research Site

    Springfield, Oregon · Recruiting

  • Research Site

    Hershey, Pennsylvania · Recruiting

  • Research Site

    Lancaster, Pennsylvania · Recruiting

  • Research Site

    Pittsburgh, Pennsylvania · Recruiting

  • Research Site

    Providence, Rhode Island · Recruiting

  • Research Site

    Myrtle Beach, South Carolina · Recruiting

  • Research Site

    Nashville, Tennessee · Recruiting

  • Research Site

    Austin, Texas · Recruiting

  • Research Site

    Austin, Texas · Recruiting

  • Research Site

    Houston, Texas · Recruiting

  • Research Site

    San Antonio, Texas · Recruiting

  • Research Site

    Spring, Texas · Recruiting

Showing 40 of 346 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.